How can we use positron emission tomography/computed tomography more accurately for characterization of asbestos-related pleural thickening?

Introduction: There is no consensus about the standardized uptake value maximum (SUV) cut-off value to characterize pleural thickening worldwide. Sometimes, this causes unnecessary invasive diagnostic procedures. Our first aim is to determine a cut-off value for SUV.

Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling.

One of the most important benign tumors in neurofibromatosis type 1 (NF1) is plexiform neurofibroma, and there is a risk of developing malignant peripheral nerve sheath tumor (MPNST) throughout life approximately 10%. However lesion characterization by anatomical imaging methods are not possible. Because of that most of cases goes to biopsy.

Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia.

Aim: The aim was to evaluate the therapeutic effectiveness of granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood mononuclear cells (PBMNCs) in critical limb ischemia (CLI) of type 2 diabetic patients.

Method: Forty diabetic patients with CLI were enrolled and randomized to treatment and control groups. In the treatment group, the patients received subcutaneous injections of recombinant human G-CSF (30 MU/day) for 5 days to mobilize stem cells.

FDG PET/CT appearance of multicentric Castleman's disease mimicking lymphoma.

We report a case of a multicentric form of Castleman's disease with multiple lymph nodes showing intense FDG uptake on whole body scan mimicking non-Hodgkin's lymphoma. In this report, the patient had multiple cervical, mediastinal, hilar, retroperitoneal and abnormal lymph nodes in the groin. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography was performed before tissue sampling.

In-vivo gamma scintigraphic evaluation and determination of a gastro-resistant etodolac tablet in humans.

A gastro-resistant (enteric coated) etodolac tablet dosage form, was evaluated by using in vitro and in vivo methods. In vitro drug release studies have shown that enteric coated tablet dosage form protects the drug from being released under conditions mimicking stomach to small intestine transit. The gastro-intestinal transit of radiolabeled 300 mg enteric coated etodolac tablets in six healthy, fed and fasted state volunteers was monitored using external gamma camera.